Alan B. Lancz & Associates, Inc. Biomarin Pharmaceutical Inc Transaction History

Alan B. Lancz & Associates, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $40,465 - $54,315	-500 Reduced 27.78%	1,300 $134,000
Q2 2022 Aug 11, 2022	SELL	$71.48 - $86.85 $3.36 Million - $4.08 Million	-47,000 Reduced 96.31%	1,800 $155,000
Q4 2021 Feb 09, 2022	BUY	$71.72 - $91.47 $3.5 Million - $4.46 Million	48,800 New	48,800 $4.31 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Alan B. Lancz & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Alan B. Lancz & Associates, Inc. with notifications on news.